The University of Wisconsin-Madison’s School of Pharmacy is hosting a Roundtable on September 27, 2022. In this hybrid roundtable, titled “Psychedelic Baselines,” a group of interdisciplinary panelists with different types of “psychedelic expertise” will discuss their research and recent activities.
Amanda Pratt spoke with Dr. Brian Pace and Dr. Neşe Devenot on July 7, 2022 about an article they recently published in Frontiers in Psychology titled “Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency.” A contribution to the Pharmaceutical Inequalities series, this audio interview sheds light on an oft-neglected aspect of psychedelic history that is essential to understand when considering the business and culture of psychedelics. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
Editor’s Note: Anny Ortiz returns with a third contribution to our Pharmaceutical Inequalities series with reflections on her recent trip to the Medical Psychedelic House of Davos to co-present alongside her colleagues from the Indigenous Medicine Conservation Fund and launch their ‘Grow Medicine’ project. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
I recently returned from a 10-day trip to Switzerland and Canada. I was in Toronto, Canada at a conference called “From Research to Reality” co-presenting a poster titled “5-MeO-DMT: Synthesis and therapeutic potential for treating psychological disorders”. It was surprising to see that there were two separate presentations by personnel from the US Food and Drug Administration (FDA), one of which was titled “Challenges in Conducting Clinical Research with Schedule I Psychedelics: From the 1960s to the Present”, presented by Dr. Katherine Bonson, and the other titled “World Regulatory and Policy Discussion: A Pathway Forward”, presented by Javier Muniz. If FDA staff presenting at a psychedelic science conference is not a sign of the times, I don’t know what is.
Immediately preceding the Toronto conference, I was in Davos, Switzerland, as part of the Indigenous Medicine Conservation Fund (IMCF), which was a sponsor of a landmark event titled “Medical Psychedelic House of Davos” (no connection to the World Economic Forum, usually hosted in Davos). I would like to share some highlights of what transpired there.
In my previous post, in this series centered around “Pharmaceutical inequalities”, I wrote about my experience working at an ibogaine clinic in Mexico. I shared that the seven-day program I developed there integrated individual counseling, group therapy, psychoeducation modules, relapse prevention education, art therapy practices, self-compassion journaling exercises, goal planning for after-care , and a 5-MeO-DMT therapy session; and that a future post would address the emerging use of 5-MeO-DMT as a mental health tool. In this second post, I am setting out to do just that.
History of Pharmacy and Pharmaceuticals, the official journal of the American Institute of the History of Pharmacy (AIHP), is pleased to announce a call for papers for a special issue: “Psychedelic Capitalism: From Forest Retreat to Fortune 500 and Pharmacies.” The issue is anticipated to appear in 2023. Guest editors for the special issue will be Drs. Neşe Devenot and Brian Pace, both of The Ohio State University.
Editor’s Note: This post by Anny Ortiz is the first in our Pharmaceutical Inequalities series. She explores the existing research landscape of psychedelics and then draws upon her own lived experience of working in a treatment center that offered ibogaine-assisted detoxification to discuss the affordances and unanswered questions of using psychedelics in treatment. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
Editor’s Note: Today’s post comes from contributing editor Peder Clark. Dr. Clark is a historian of modern Britain, with research interests in drugs, subcultures, health, everyday life, and visual culture. He completed his PhD in 2019 at the London School of Hygiene and Tropical Medicine (LSHTM) and currently holds a position at the University of Strathclyde.
“Taking Drugs To Make Music To Take Drugs To”, the title of British indie band Spacemen 3’s 1990 album, sums up for many the symbiotic relationship between rock music and psychoactive substances. From “Cocaine Blues” to Jefferson Airplane and from “Feel Good Hit of the Summer” to Amy Winehouse, rock’s back pages are soaked in the celebration, inspiration, and (sometimes) repudiation of drug-fueled intoxication.
The conspicuous consumption of drugs—or winking allusions to drugs—is a tried-and-tested way for young musicians to illustrate their edginess, to promote their counter-cultural associations, and to make real the moral danger that they might feel is inherent in the art-form. No need, however, to bore Points readers with musings better suited to ghost-written Keith Richards memoirs.
What about musicians that aim for a more considered, less debauched approach to chemically-enhanced states of mind? This is all by way of introduction to a recent bubbling up of psychedelic consciousness amongst musicians of a certain vintage—and a renewed attention to the role of music in psychedelic therapy.